Sandoz Group AG SDZNY
Set alert
100.40 USD -0.66 -0.65%
As of Nov 3, 2:54 PM ET
100.40 Day range 101.28
65.31 52-week range 103.22
- YTD
- +37.95%
- 1 year
- +46.53%
- Open
- 101.28
- Prev close
- 101.06
- Mkt cap
- 43.55B
- Vol
- 750
- Avg vol
- 24.66K
- EPS
- 1.47
- P/E
- 68.30
More statistics
- Low
- 100.40
- High
- 101.28
2Y chart
Events in this range
- Apr 22, 2025Dividend: 0.72722
- Aug 7, 2025Earnings: 0.864; estimate —; surprise —%
- Mar 3, 2026Earnings: 1.58; estimate —; surprise —%
- Apr 14, 2026Dividend: 1.02074
Signals (91)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 29, 2026 | 5 days ago |
| RSI: Overbought | Oct 21, 2026 | 1 week ago |
| RSI: Overbought | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 7, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 6, 2026 | 4 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 4 weeks ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 2 months ago |
| SMA: Bullish | Sep 3, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 3 months ago |
Newest 20 of 91.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 3, 2026 | Dec 31, 2025 | — | 1.58 | — | — |
| Aug 7, 2025 | Jun 30, 2025 | — | 0.864 | — | — |
News
- Sandoz Group AG (SDZNY) Q3 2026 Sales/Trading Call Transcript
- Sandoz Shares Fall After Company Turns Cautious on Sales Guidance
- Generic drugmaker Sandoz lowers sales outlook, lifts profit forecast
- NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?
- GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
- mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide
- Sandoz Gets Canada Approval for Generic Version of Ozempic
- Sandoz Group AG (SDZNY) Analyst/Investor Day Transcript
- GRFS or SDZNY: Which Is the Better Value Stock Right Now?
- Switzerland's Sandoz pivots to biosimilars, expects rapid mid-term growth
Your note
Sign in to keep a note on SDZNY — it syncs with the Stock Master app.